Brigatinib is a highly potent and selective investigational ALK inhibitor with mean IC50 value £¼ 100 nM in Ba/F3 cells. IC50 value: £¼ 100 nM Target: pan-ALK in vitro: Brigatinib inhibits all 17 ALK mutants previously observed to confer resistance to Crizotinib, Ceritinib, and/or Alectinib. in vivo: Brigatinib uniquely maintains substantial activity against the highly recalcitrant G1202R mutant. Brigatinib has exhibited promising antitumor activity in patients with Crizotinib-resistant disease in an ongoing phase 1/2 clinical trial.

June 21, 2017

prudect name : Brigatinib is a highly potent and selective investigational ALK inhibitor with mean IC50 value £¼ 100 nM in Ba/F3 cells. IC50 value: £¼ 100 nM Target: pan-ALK in vitro: Brigatinib inhibits all 17 ALK mutants previously observed to confer resistance to Crizotinib, Ceritinib, and/or Alectinib. in vivo: Brigatinib uniquely maintains substantial activity against the highly recalcitrant G1202R mutant. Brigatinib has exhibited promising antitumor activity in patients with Crizotinib-resistant disease in an ongoing phase 1/2 clinical trial.
Brigatinib (AP-26113)

Synonyms: CAS NO: 1197953-54-0Molecular Formula: C₂₉H₃₉ClN₇O₂PMolecular Weight: 584.09Purity: 98% minSolubility: DMSOStorage: -20¡æ

TTP488 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18505476